Certara Signs Research Agreement with The Hamner Institutes for Health Sciences
August 20, 2013 at 05:30 pm IST
Share
Certara announced that it has signed a research agreement with The Hamner Institutes for Health Sciences. Under this research agreement, Certara and The Hamner will explore the scientific benefits of using Certara's Simcyp(TM) Simulator to drive hepatic drug exposure within The Hamner's population-based, drug-induced liver injury (DILI) model. The partners plan to integrate The Hamner's DILIsym(R) modeling software into Certara's Simcyp Population-based Simulator and test the integrated product's simulation capabilities with respect to drug exposure and resultant liver toxicity.
Both of these systems are used by several international pharmaceutical companies.
Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development in the global biopharmaceutical industry. It is focused on producing medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its customers include life sciences companies of all sizes along with contract research organizations, academic institutions, and global regulators. Its software and service are used by approximately 2,400 biopharmaceutical companies and academic institutions across 66 countries, including 38 of the top 40 biopharmaceutical companies. It has operations in the United States, Australia, Canada, China, France, Germany, India, Italy, Japan, Luxembourg, Netherlands, Philippines, Poland, Portugal, Spain, Switzerland, Egypt, and the United Kingdom.
CERTARA, INC. 
